Invitae (NYSE:NVTA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Invitae (NYSE:NVTA) in a research note released on Wednesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Invitae Stock Performance

Shares of NVTA stock opened at $0.00 on Wednesday. Invitae has a 12 month low of $0.02 and a 12 month high of $0.02. The firm has a market capitalization of $80,103.00, a PE ratio of 0.00 and a beta of 1.59.

Hedge Funds Weigh In On Invitae

An institutional investor recently bought a new position in Invitae stock. Vestmark Advisory Solutions Inc. bought a new position in shares of Invitae Co. (NYSE:NVTA) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 839,007 shares of the medical research company’s stock, valued at approximately $526,000. Vestmark Advisory Solutions Inc. owned approximately 0.29% of Invitae as of its most recent filing with the Securities & Exchange Commission. 61.28% of the stock is currently owned by institutional investors.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.